Disease-A-Month
Volume 54, Issue 7 , Pages 457-485 , July 2008

Acute Liver Failure

References 

  1. Khashab M, Tector AJ, Kwo PY. Epidemiology of acute liver failure. Curr Gastroenterol Rep. 2007;9:66–73
  2. Bower WA, Johns M, Margolis HS, et al. Population-based surveillance for acute liver failure. Am J Gastroenterol. 2007;102:2459–2463
  3. Hoofnagle JH, Carithers RL, Shapiro C, et al. Fulminant hepatic failure: summary of a workshop. Hepatology. 1995;21:240–252
  4. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947–954
  5. O'Grady J. Modern management of acute liver failure. Clin Liver Dis. 2007;11:291–303
  6. Farmer DG, Anselmo DM, Ghobrial RM, et al. Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg. 2003;237:666–675
  7. Brandsaeter B, Hockerstedt K, Friman S, et al. Fulminant hepatic failure: outcome after listing for highly urgent liver transplantation—12 years experience in the Nordic countries. Liver Transpl. 2002;8:1055–1062
  8. Karvountzis GG, Redeker AG, Peters RL. Long term follow-up studies of patients surviving fluminant viral hepatitis. Gastroenterology. 1974;67:870–877
  9. Trey C, Davidson CS. The management of fulminant hepatic failure. In:  Pooper H,  Schaffner F editor. Progress in Liver Diseases. New York, NY: Grune & Stratton; 1970;p. 282–298
  10. O'Grady JG, Schalm SW, Williams R. Acute liver failure: redefining the syndromes. Lancet. 1993;342:273–275
  11. Tandon BN, Bernauau J, O'Grady J, et al. Recommendations of the International Association for the Study of the Liver Subcommittee on nomenclature of acute and subacute liver failure. J Gastroenterol Hepatol. 1999;14:403–404
  12. Polson J, Lee WM. AASLD position paper: the management of acute liver failure. Hepatology. 2005;41:1179–1197
  13. O'Grady JG, Alexander GJ, Hayllar KM, et al. Early indicators of prognosis in fulminant hepatic failure. Gastroenterology. 1989;97:439–445
  14. Makin AJ, Wendon J, Williams R. A 7-year experience of severe acetaminophen-induced hepatotoxicity (1987-1993). Gastroenterology. 1995;109:1907–1916
  15. Ayonrinde OT, Phelps GJ, Hurley JC, et al. Paracetamol overdose and hepatotoxicity at a regional Australian hospital: a 4-year experience. Intern Med J. 2005;35:655–660
  16. Acharya SK, Panda SK, Saxena A, et al. Acute hepatic failure in India: a perspective from the East. J Gastroenterol Hepatol. 2000;15:473–479
  17. Ostapowicz G, Lee WM. Acute hepatic failure: a Western perspective. J Gastroenterol Hepatol. 2000;15:480–488
  18. Khan SA, Shah N, Williams R, et al. Acute liver failure: a review. Clin Liver Dis. 2006;10:239–258vii-viii
  19. Larson AM, Polson J, Fontana RJ, et al. Acetaminophen-induced acute liver failure: results of a United States multicenter, prospective study. Hepatology. 2005;42:1364–1372
  20. Williams R. Classification, etiology, and considerations of outcome in acute liver failure. Semin Liver Dis. 1996;16:343–348
  21. Schiodt FV, Atillasoy E, Shakil AO, et al. Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg. 1999;5:29–34
  22. Williams R, Riordan SM. Acute liver failure: established and putative hepatitis viruses and therapeutic implications. J Gastroenterol Hepatol. 2000;15(suppl):G17–G25
  23. Liu CJ, Kao JH, Lai MY, et al. Minimal role of GB virus-C/hepatitis G virus in fulminant and subfulminant hepatitis in Taiwan. J Gastroenterol Hepatol. 1999;14:352–357
  24. Jain A, Kar P, Madan K, et al. Hepatitis C virus infection in sporadic fulminant viral hepatitis in North India: cause or co-factor?. Eur J Gastroenterol Hepatol. 1999;11:1231–1237
  25. Madan K, Gopalkrishna V, Kar P, et al. Detection of hepatitis C and E virus genomes in sera of patients with acute viral hepatitis and fulminant hepatitis by their simultaneous amplification in PCR. J Gastroenterol Hepatol. 1998;13:125–130
  26. Ritt DJ, Whelan G, Werner DJ, et al. Acute hepatic necrosis with stupor or coma (An analysis of thirty-one patients). Medicine (Baltimore). 1969;48:151–172
  27. Lefilliatre P, Villeneuve JP. Fulminant hepatitis A in patients with chronic liver disease. Can J Public Health. 2000;91:168–170
  28. Lednar WM, Lemon SM, Kirkpatrick JW, et al. Frequency of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol. 1985;122:226–233
  29. Hadler SC, Webster HM, Erben JJ, et al. Hepatitis A in day-care centers (A community-wide assessment). N Engl J Med. 1980;302:1222–1227
  30. Benenson MW, Takafuji ET, Bancroft WH, et al. A military community outbreak of hepatitis type A related to transmission in a child care facility. Am J Epidemiol. 1980;112:471–481
  31. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997;337:1733–1745
  32. Forbes A, Alexander GJ, Smith HM, et al. Elevation of serum sex hormone-binding globulin in females with fulminant hepatitis B virus infection. J Med Virol. 1988;26:93–98
  33. Fagan EA, Williams R. Fulminant viral hepatitis. Br Med Bull. 1990;46:462–480
  34. Fagan EA, Harrison TJ. Exclusion in liver by polymerase chain reaction of hepatitis B and C viruses in acute liver failure attributed to sporadic non-A, non-B hepatitis. J Hepatol. 1994;21:587–591
  35. Wright TL. Etiology of fulminant hepatic failure: is another virus involved?. Gastroenterology. 1993;104:640–643
  36. Feray C, Gigou M, Samuel D, et al. Hepatitis C virus RNA and hepatitis B virus DNA in serum and liver of patients with fulminant hepatitis. Gastroenterology. 1993;104:549–555
  37. Wright TL, Mamish D, Combs C, et al. Hepatitis B virus and apparent fulminant non-A, non-B hepatitis. Lancet. 1992;339:952–955
  38. Kuwada SK, Patel VM, Hollinger FB, et al. Non-A, non-B fulminant hepatitis is also non-E and non-C. Am J Gastroenterol. 1994;89:57–61
  39. Bryan JP, Tsarev SA, Iqbal M, et al. Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease. J Infect Dis. 1994;170:517–521
  40. Liang TJ, Jeffers L, Reddy RK, et al. Fulminant or subfulminant non-A, non-B viral hepatitis: the role of hepatitis C and E viruses. Gastroenterology. 1993;104:556–562
  41. Norvell JP, Blei AT, Jovanovic BD, et al. Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl. 2007;13:1428–1434
  42. Abbo L, Alcaide ML, Pano JR, et al. Fulminant hepatitis from herpes simplex virus type 2 in an immunocompetent adult. Transpl Infect Dis. 2007;9:323–326
  43. Rodriguez-Moreno A, Sanchez-Fructuoso AI, Calvo N, et al. Varicella infection in adult renal allograft recipients: experience at one center. Transplant Proc. 2006;38:2416–2418
  44. Anderson DR, Schwartz J, Hunter NJ, et al. Varicella hepatitis: a fatal case in a previously healthy, immunocompetent adult (Report of a case, autopsy, and review of the literature). Arch Intern Med. 1994;154:2101–2106
  45. Matsumoto A, Yeo AE, Shih JW, et al. Transfusion-associated TT virus infection and its relationship to liver disease. Hepatology. 1999;30:283–288
  46. Nishizawa T, Okamoto H, Konishi K, et al. A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun. 1997;241:92–97
  47. Umemura T, Yeo AE, Sottini A, et al. SEN virus infection and its relationship to transfusion-associated hepatitis. Hepatology. 2001;33:1303–1311
  48. Umemura T, Tanaka E, Ostapowicz G, et al. Investigation of SEN virus infection in patients with cryptogenic acute liver failure, hepatitis-associated aplastic anemia, or acute and chronic non-A-E hepatitis. J Infect Dis. 2003;188:1545–1552
  49. Funaoka M, Kato K, Komatsu M, et al. Fulminant hepatitis caused by hepatitis C virus during treatment for multiple sclerosis. J Gastroenterol. 1996;31:119–122
  50. Gordon FD, Anastopoulos H, Khettry U, et al. Hepatitis C infection: a rare cause of fulminant hepatic failure. Am J Gastroenterol. 1995;90:117–120
  51. Ben-Ari Z, Samuel D, Zemel R, et al. Fulminant non–A-G viral hepatitis leading to liver transplantation. Arch Intern Med. 2000;160:388–392
  52. Holt MP, Ju C. Mechanisms of drug-induced liver injury. AAPS J. 2006;8:E48–E54
  53. Temple RJ, Himmel MH. Safety of newly approved drugs: implications for prescribing. JAMA. 2002;287:2273–2275
  54. Kava-containing dietary supplements may be associated with severe liver injury. 2002 http://www.cfsan.fda.gov∼dms/addskava.htmlAccessed May 13, 2008
  55. Murphy EJ, Davern TJ, Shakil AO, et al. Troglitazone-induced fulminant hepatic failure Acute Liver Failure (Study Group). Dig Dis Sci. 2000;45:549–553
  56. Fontana RJ, McCashland TM, Benner KG, et al. Acute liver failure associated with prolonged use of bromfenac leading to liver transplantation (The Acute Liver Failure Study Group). Liver Transpl Surg. 1999;5:480–484
  57. Nourjah P, Rizwanuddin A, Karwoski C, et al. Estimates of acetaminophen (paracetomal)-associated overdoses in the United States. Pharmacoepidemiol Drug Saf. 2006;15:398–405
  58. McJunkin B, Barwick KW, Little WC, et al. Fatal massive hepatic necrosis following acetaminophen overdose. JAMA. 1976;236:1874–1875
  59. Thomson JS, Prescott LF. Liver damage and impaired glucose tolerance after paracetamol overdosage. BMJ. 1966;2:506–507
  60. Davidson DG, Eastham WN. Acute liver necrosis following overdose of paracetamol. BMJ. 1966;2:497–499
  61. Boyd EM, Bereczky GM. Liver necrosis from paracetamol. Br J Pharmacol Chemother. 1966;26:606–614
  62. Schiodt FV, Rochling FA, Casey DL, et al. Acetaminophen toxicity in an urban county hospital. N Engl J Med. 1997;337:1112–1117
  63. Slattery JT, Nelson SD, Thummel KE. The complex interaction between ethanol and acetaminophen. Clin Pharmacol Ther. 1996;60:241–246
  64. Zimmerman HJ, Maddrey WC. Acetaminophen (paracetamol) hepatotoxicity with regular intake of alcohol: analysis of instances of therapeutic misadventure. Hepatology. 1995;22:767–773
  65. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994;272:1845–1850
  66. Seeff LB, Cuccherini BA, Zimmerman HJ, et al. Acetaminophen hepatotoxicity in alcoholics (A therapeutic misadventure). Ann Intern Med. 1986;104:399–404
  67. Zimmerman HJ. Effects of aspirin and acetaminophen on the liver. Arch Intern Med. 1981;141:333–342
  68. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296:87–93
  69. Kuffner EK, Temple AR, Cooper KM, et al. Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials. Curr Med Res Opin. 2006;22:2137–2148
  70. Forrest JA, Clements JA, Prescott LF. Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet. 1982;7:93–107
  71. Manyike PT, Kharasch ED, Kalhorn TF, et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther. 2000;67:275–282
  72. Chen W, Koenigs LL, Thompson SJ, et al. Oxidation of acetaminophen to its toxic quinone imine and nontoxic catechol metabolites by baculovirus-expressed and purified human cytochromes P450 2E1 and 2A6. Chem Res Toxicol. 1998;11:295–301
  73. Thummel KE, Lee CA, Kunze KL, et al. Oxidation of acetaminophen to N-acetyl-p-aminobenzoquinone imine by human CYP3A4. Biochem Pharmacol. 1993;45:1563–1569
  74. Corcoran GB, Mitchell JR, Vaishnav YN, et al. Evidence that acetaminophen and N-hydroxyacetaminophen form a common arylating intermediate, N-acetyl-p-benzoquinoneimine. Mol Pharmacol. 1980;18:536–542
  75. Sarich T, Kalhorn T, Magee S, et al. The effect of omeprazole pretreatment on acetaminophen metabolism in rapid and slow metabolizers of S-mephenytoin. Clin Pharmacol Ther. 1997;62:21–28
  76. Graham GG, Scott KF, Day RO. Tolerability of paracetamol. Drug Saf. 2005;28:227–240
  77. Kaplowitz N. Acetaminophen hepatoxicity: what do we know, what don't we know, and what do we do next?. Hepatology. 2004;40:23–26
  78. Mitchell JR, Thorgeirsson SS, Potter WZ, et al. Acetaminophen-induced hepatic injury: protective role of glutathione in man and rationale for therapy. Clin Pharmacol Ther. 1974;16:676–684
  79. Mitchell JR, Jollow DJ, Potter WZ, et al. Acetaminophen-induced hepatic necrosis (IV. Protective role of glutathione). J Pharmacol Exp Ther. 1973;187:211–217
  80. Davis M. Protective agents for acetaminophen overdose. Semin Liver Dis. 1986;6:138–147
  81. Rumack BH, Matthew H. Acetaminophen poisoning and toxicity. Pediatrics. 1975;55:871–876
  82. Mutlib AE, Goosen TC, Bauman JN, et al. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15 (Potential implications in acetaminophen-induced hepatotoxicity). Chem Res Toxicol. 2006;19:701–709
  83. Rumack BH. Acetaminophen hepatotoxicity: the first 35 years. J Toxicol Clin Toxicol. 2002;40:3–20
  84. Prescott LF. Paracetamol, alcohol and the liver. Br J Clin Pharmacol. 2000;49:291–301
  85. Chanda S, Mehendale HM. Role of nutrition in the survival after hepatotoxic injury. Toxicology. 1996;111:163–178
  86. Bray GP, Harrison PM, O'Grady JG, et al. Long-term anticonvulsant therapy worsens outcome in paracetamol-induced fulminant hepatic failure. Hum Exp Toxicol. 1992;11:265–270
  87. Goldfinger R, Ahmed KS, Pitchumoni CS, et al. Concomitant alcohol and drug abuse enhancing acetaminophen toxicity (Report of a case). Am J Gastroenterol. 1978;70:385–388
  88. Gow PJ, Jones RM, Dobson JL, et al. Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol. 2004;19:154–159
  89. Gow PJ, Smallwood RA, Angus PW. Paracetamol overdose in a liver transplantation centre: an 8-year experience. J Gastroenterol Hepatol. 1999;14:817–821
  90. Litovitz TL, Smilkstein M, Felberg L, et al. 1996 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 1997;15:447–500
  91. Makin A, Williams R. The current management of paracetamol overdosage. Br J Clin Pract. 1994;48:144–148
  92. Escudie L, Francoz C, Vinel JP, et al. Amanita phalloides poisoning: reassessment of prognostic factors and indications for emergency liver transplantation. J Hepatol. 2007;46:466–473
  93. Erguven M, Yilmaz O, Deveci M, et al. Mushroom poisoning. Indian J Pediatr. 2007;74:847–852
  94. Joshi A, Awale P, Shrestha A, et al. Acute mushroom poisoning: a report of 41 cases. JNMA J Nepal Med Assoc. 2007;46:7–12
  95. Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med. 2005;33:427–436
  96. Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med. 2005;33:419–426
  97. Enjalbert F, Rapior S, Nouguier-Soule J, et al. Treatment of amatoxin poisoning: 20-year retrospective analysis. J Toxicol Clin Toxicol. 2002;40:715–757
  98. Larrey D, Pageaux GP. Hepatotoxicity of herbal remedies and mushrooms. Semin Liver Dis. 1995;15:183–188
  99. Gill RQ, Sterling RK. Acute liver failure. J Clin Gastroenterol. 2001;33:191–198
  100. Scheurlen C, Spannbrucker N, Spengler U, et al. Amanita phalloides intoxications in a family of Russian immigrants (Case reports and review of the literature with a focus on orthotopic liver transplantation). Z Gastroenterol. 1994;32:399–404
  101. Ganzert M, Felgenhauer N, Zilker T. Reassessment of predictors of fatal outcome in amatoxin poisoning: some critical comments. J Hepatol. 2007;47:424–425
  102. Ganzert M, Felgenhauer N, Zilker T. Indication of liver transplantation following amatoxin intoxication. J Hepatol. 2005;42:202–209
  103. Pinson CW, Daya MR, Benner KG, et al. Liver transplantation for severe Amanita phalloides mushroom poisoning. Am J Surg. 1990;159:493–499
  104. Zimmerman HJ. Drug-induced liver disease. In:  Schiff E,  Sorrell M,  Maddrey W editor. Schiff's Diseases of the Liver. Philadelphia, PA: Lippincott-Raven; 1999;p. 973
  105. Castell JV, Castell M. Allergic hepatitis induced by drugs. Curr Opin Allergy Clin Immunol. 2006;6:258–265
  106. Castell JV. Allergic hepatitis: a drug-mediated organ-specific immune reaction. Clin Exp Allergy. 1998;28(suppl 4):13–19
  107. Gomez-Lechon MJ, Carrasquer J, Berenguer J, et al. Evidence of antibodies to erythromycin in serum of a patient following an episode of acute drug-induced hepatitis. Clin Exp Allergy. 1996;26:590–596
  108. Lewis JH. Medication-related and other forms of toxic liver injury. In:  Brandt LJ editors. Clinical Practice of Gastroenterology. Philadelphia, PA: Churchill Livingstone; 1998;p. 855
  109. Henrion J. Hypoxic hepatitis: the point of view of the clinician. Acta Gastroenterol Belg. 2007;70:214–216
  110. Birrer R, Takuda Y, Takara T. Hypoxic hepatopathy: pathophysiology and prognosis. Intern Med. 2007;46:1063–1070
  111. van Riel JM, Kerremans AL. [Ischemic hepatitis]. Ned Tijdschr Geneeskd. 1992;136:2078–2081
  112. Segev DL, Nguyen GC, Locke JE, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: a national registry analysis. Liver Transpl. 2007;13:1285–1294
  113. Dellon ES, Morris SR, Tang W, et al. Acute liver failure due to natural killer-like T-cell leukemia/lymphoma: a case report and review of the literature. World J Gastroenterol. 2006;12:4089–4092
  114. Alexopoulou A, Koskinas J, Deutsch M, et al. Acute liver failure as the initial manifestation of hepatic infiltration by a solid tumor: report of 5 cases and review of the literature. Tumori. 2006;92:354–357
  115. Rajvanshi P, Kowdley KV, Hirota WK, et al. Fulminant hepatic failure secondary to neoplastic infiltration of the liver. J Clin Gastroenterol. 2005;39:339–343
  116. El-Sayed MH, El-Haddad A, Fahmy OA, et al. Liver disease is a major cause of mortality following allogeneic bone-marrow transplantation. Eur J Gastroenterol Hepatol. 2004;16:1347–1354
  117. Stillman AS, Huxtable R, Consroe P, et al. Hepatic veno-occlusive disease due to pyrrolizidine (Senecio) poisoning in Arizona. Gastroenterology. 1977;73:349–352
  118. Larson AM. Liver disease in pregnancy. Clin Perspect Gastroenterol. 2001;4:351–357
  119. Santos RG, Alissa F, Reyes J, et al. Fulminant hepatic failure: Wilson's disease or autoimmune hepatitis? (Implications for transplantation). Pediatr Transplant. 2005;9:112–116
  120. Kessler WR, Cummings OW, Eckert G, et al. Fulminant hepatic failure as the initial presentation of acute autoimmune hepatitis. Clin Gastroenterol Hepatol. 2004;2:625–631
  121. Herzog D, Rasquin-Weber AM, Debray D, et al. Subfulminant hepatic failure in autoimmune hepatitis type 1: an unusual form of presentation. J Hepatol. 1997;27:578–582
  122. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology. 1993;18:998–1005
  123. Porta G, Gayotto LC, Alvarez F. Anti-liver-kidney microsome antibody-positive autoimmune hepatitis presenting as fulminant liver failure. J Pediatr Gastroenterol Nutr. 1990;11:138–140
  124. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006;354:54–66
  125. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology. 2002;36:479–497
  126. Davis GL, Czaja AJ, Baggenstoss AH, et al. Prognostic and therapeutic implications of extreme serum aminotransferase elevation in chronic active hepatitis. Mayo Clin Proc. 1982;57:303–309
  127. Wilson SAK. Progressive lenticular degeneration: a familial nervous disease associated with cirrhosis of the liver. Brain. 1912;34:20–509
  128. Ala A, Schilsky ML. Wilson disease: pathophysiology, diagnosis, treatment, and screening. Clin Liver Dis. 2004;8:787–805viii
  129. Frydman M. Genetic aspects of Wilson's disease. J Gastroenterol Hepatol. 1990;5:483–490
  130. Bull PC, Thomas GR, Rommens JM, et al. The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet. 1993;5:327–337
  131. Tanzi RE, Petrukhin K, Chernov I, et al. The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet. 1993;5:344–350
  132. Yamaguchi Y, Heiny ME, Gitlin JD. Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun. 1993;197:271–277
  133. Beyersdorff A, Findeisen A. Morbus Wilson: case report of a two-year-old child as first manifestation. Scand J Gastroenterol. 2006;41:496–497
  134. Ala A, Borjigin J, Rochwarger A, Schilsky M. Wilson disease in septuagenarian siblings: raising the bar for diagnosis. Hepatology. 2005;41:668–670
  135. Roberts EA, Schilsky ML. A practice guideline on Wilson disease. Hepatology. 2003;37:1475–1492
  136. Bellary SV, Van Thiel DH. Wilson's disease: a diagnosis made in two individuals greater than 40 years of age. J Okla State Med Assoc. 1993;86:441–444
  137. Schoen RE, Sternlieb I. Clinical aspects of Wilson's disease. Am J Gastroenterol. 1990;85:1453–1457
  138. Merle U, Schaefer M, Ferenci P, et al. Clinical presentation, diagnosis and long-term outcome of Wilson's disease: a cohort study. Gut. 2007;56:115–120
  139. Gitlin JD. Wilson disease. Gastroenterology. 2003;125:1868–1877
  140. Stremmel W, Meyerrose KW, Niederau C, et al. Wilson disease: clinical presentation, treatment, and survival. Ann Intern Med. 1991;115:720–726
  141. Eisenbach C, Sieg O, Stremmel W, et al. Diagnostic criteria for acute liver failure due to Wilson disease. World J Gastroenterol. 2007;13:1711–1714
  142. McCullough AJ, Fleming CR, Thistle JL, et al. Diagnosis of Wilson's disease presenting as fulminant hepatic failure. Gastroenterology. 1983;84:161–167
  143. Emre S, Atillasoy EO, Ozdemir S, et al. Orthotopic liver transplantation for Wilson's disease: a single-center experience. Transplantation. 2001;72:1232–1236
  144. Sallie R, Katsiyiannakis L, Baldwin D, et al. Failure of simple biochemical indexes to reliably differentiate fulminant Wilson's disease from other causes of fulminant liver failure. Hepatology. 1992;16:1206–1211
  145. Berman DH, Leventhal RI, Gavaler JS, et al. Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. Gastroenterology. 1991;100:1129–1134
  146. Shaver WA, Bhatt H, Combes B. Low serum alkaline phosphatase activity in Wilson's disease. Hepatology. 1986;6:859–863
  147. Stravitz RT, Kramer AH, Davern T, et al. Intensive care of patients with acute liver failure: recommendations of the U.S. Acute Liver Failure Study Group. Crit Care Med. 2007;35:2498–2508
  148. Jalan R. Acute liver failure: current management and future prospects. J Hepatol. 2005;42(suppl):S115–S123
  149. Isobe-Harima Y, Terai S, Miura I, et al. A new hepatic encephalopathy model to monitor the change of neural amino acids and astrocytes with behaviour disorder. Liver Int. 2007;28:117–125
  150. Bernal W, Hall C, Karvellas CJ, et al. Arterial ammonia and clinical risk factors for encephalopathy and intracranial hypertension in acute liver failure. Hepatology. 2007;46:1844–1852
  151. Bhatia V, Singh R, Acharya SK. Predictive value of arterial ammonia for complications and outcome in acute liver failure. Gut. 2006;55:98–104
  152. Belanger M, Butterworth RF. Acute liver failure: a critical appraisal of available animal models. Metab Brain Dis. 2005;20:409–423
  153. Ellis AJ, Wendon JA, Williams R. Subclinical seizure activity and prophylactic phenytoin infusion in acute liver failure: a controlled clinical trial. Hepatology. 2000;32:536–541
  154. Bhatia V, Batra Y, Acharya SK. Prophylactic phenytoin does not improve cerebral edema or survival in acute liver failure—a controlled clinical trial. J Hepatol. 2004;41:89–96
  155. Conn HO. Trailmaking and number-connection tests in the assessment of mental state in portal systemic encephalopathy. Am J Dig Dis. 1977;22:541–550
  156. Conn HO. The recognition and management of hepatic coma. J Newark Beth Isr Hosp. 1961;12:12–20
  157. Alba L, Hay J, Angelo P, et al. Lactulose therapy in acute liver failure. (abstract) J Hepatol. 2002;36:33A
  158. Munoz SJ. Difficult management problems in fulminant hepatic failure. Semin Liver Dis. 1993;13:395–413
  159. Wright G, Shawcross D, Olde Damink SW, et al. Brain cytokine flux in acute liver failure and its relationship with intracranial hypertension. Metab Brain Dis. 2007;22:375–388
  160. Ott P, Larsen FS. Blood-brain barrier permeability to ammonia in liver failure: a critical reappraisal. Neurochem Int. 2004;44:185–198
  161. Blei AT, Larsen FS. Pathophysiology of cerebral edema in fulminant hepatic failure. J Hepatol. 1999;31:771–776
  162. Ware AJ, D'Agostino AN, Combes B. Cerebral edema: a major complication of massive hepatic necrosis. Gastroenterology. 1971;61:877–884
  163. Williams R, Gimson AE. Intensive liver care and management of acute hepatic failure. Dig Dis Sci. 1991;36:820–826
  164. Schafer DF, Shaw BW. Fulminant hepatic failure and orthotopic liver transplantation. Semin Liver Dis. 1989;9:189–194
  165. Bass NM. Monitoring and treatment of intracranial hypertension. Liver Transpl. 2000;6:S21–S26
  166. Vaquero J, Fontana RJ, Larson AM, et al. Complications and use of intracranial pressure monitoring in patients with acute liver failure and severe encephalopathy. Liver Transpl. 2005;11:1581–1589
  167. Bernuau J, Durand F. Intracranial pressure monitoring in patients with acute liver failure: a questionable invasive surveillance. Hepatology. 2006;44:502–504
  168. Lidofsky SD, Bass NM, Prager MC, et al. Intracranial pressure monitoring and liver transplantation for fulminant hepatic failure. Hepatology. 1992;16:1–7
  169. Munoz SJ, Moritz MJ, Martin P, et al. Relationship between cerebral perfusion pressure and systemic hemodynamics in fulminant hepatic failure. Transplant Proc. 1993;25:1776–1778
  170. Forbes A, Alexander GJ, O'Grady JG, et al. Thiopental infusion in the treatment of intracranial hypertension complicating fulminant hepatic failure. Hepatology. 1989;10:306–310
  171. Jalan R, Rose C. Hypothermia in acute liver failure. Metab Brain Dis. 2004;19:215–221
  172. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg. 2007;24:250–258
  173. Harrison PM, O'Grady JG, Keays RT, et al. Serial prothrombin time as prognostic indicator in paracetamol induced fulminant hepatic failure. BMJ. 1990;301:964–966
  174. Gimson AE, Braude S, Mellon PJ, et al. Earlier charcoal haemoperfusion in fulminant hepatic failure. Lancet. 1982;2:681–683
  175. O'Grady JG, Langley PG, Isola LM, et al. Coagulopathy of fulminant hepatic failure. Semin Liver Dis. 1986;6:159–163
  176. Trewby PN, Warren R, Contini S, et al. Incidence and pathophysiology of pulmonary edema in fulminant hepatic failure. Gastroenterology. 1978;74:859–865
  177. Baudouin SV, Howdle P, O'Grady JG, et al. Acute lung injury in fulminant hepatic failure following paracetamol poisoning. Thorax. 1995;50:399–402
  178. Williams A, Trewby P, Williams R, et al. Structural alterations to the pulmonary circulation in fulminant hepatic failure. Thorax. 1979;34:447–453
  179. Kostopanagiotou G, Routsi C, Smyrniotis V, et al. Alterations in bronchoalveolar lavage fluid during ischemia-induced acute hepatic failure in the pig. Hepatology. 2003;37:1130–1138
  180. Wilkinson SP, Moodie H, Arroyo VA, et al. Frequency of renal impairment in paracetamol overdose compared with other causes of acute liver damage. J Clin Pathol. 1977;30:141–143
  181. Ring-Larsen H, Palazzo U. Renal failure in fulminant hepatic failure and terminal cirrhosis: a comparison between incidence, types, and prognosis. Gut. 1981;22:585–591
  182. Wilkinson SP, Portmann B, Hurst D, et al. Pathogenesis of renal failure in cirrhosis and fulminant hepatic failure. Postgrad Med J. 1975;51:503–505
  183. Guarner F, Hughes RD, Gimson AE, et al. Renal function in fulminant hepatic failure: haemodynamics and renal prostaglandins. Gut. 1987;28:1643–1647
  184. Sussman NL. Fulminant hepatic failure. In:  Zakim D,  Boyer TD editor. Hepatology (A Textbook of Liver Disease). 3rd ed.. Philadelphia, PA: W.B. Saunders Co; 1996;p. 618–650
  185. Wilkinson SP, Blendis LM, Williams R. Frequency and type of renal and electrolyte disorders in fulminant hepatic failure. BMJ. 1974;1:186–189
  186. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. Crit Care Med. 1993;21:328–338
  187. Bihari D, Gimson AE, Waterson M, et al. Tissue hypoxia during fulminant hepatic failure. Crit Care Med. 1985;13:1034–1039
  188. Bihari D, Gimson AE, Lindridge J, et al. Lactic acidosis in fulminant hepatic failure (Some aspects of pathogenesis and prognosis). J Hepatol. 1985;1:405–416
  189. Ellis A, Wendon J. Circulatory, respiratory, cerebral, and renal derangements in acute liver failure: pathophysiology and management. Semin Liver Dis. 1996;16:379–388
  190. Wilkinson SP, Arroyo V, Gazzard BG, et al. Relation of renal impairment and haemorrhagic diathesis to endotoxaemia in fulminant hepatic failure. Lancet. 1974;1:521–524
  191. Iwai H, Nagaki M, Naito T, et al. Removal of endotoxin and cytokines by plasma exchange in patients with acute hepatic failure. Crit Care Med. 1998;26:873–876
  192. Nagaki M, Iwai H, Naiki T, et al. High levels of serum interleukin-10 and tumor necrosis factor-alpha are associated with fatality in fulminant hepatitis. J Infect Dis. 2000;182:1103–1108
  193. Rolando N, Harvey F, Brahm J, et al. Fungal infection: a common, unrecognised complication of acute liver failure. J Hepatol. 1991;12:1–9
  194. Salmeron JM, Tito L, Rimola A, et al. Selective intestinal decontamination in the prevention of bacterial infection in patients with acute liver failure. J Hepatol. 1992;14:280–285
  195. Rolando N, Harvey F, Brahm J, et al. Prospective study of bacterial infection in acute liver failure: an analysis of fifty patients. Hepatology. 1990;11:49–53
  196. Vaquero J, Polson J, Chung C, et al. Infection and the progression of hepatic encephalopathy in acute liver failure. Gastroenterology. 2003;125:755–764
  197. Bernal W. Changing patterns of causation and the use of transplantation in the United kingdom. Semin Liver Dis. 2003;23:227–237
  198. Rolando N, Philpott-Howard J, Williams R. Bacterial and fungal infection in acute liver failure. Semin Liver Dis. 1996;16:389–402
  199. Rolando N, Wade J, Davalos M, et al. The systemic inflammatory response syndrome in acute liver failure. Hepatology. 2000;32:734–739
  200. Shakil AO, Kramer D, Mazariegos GV, et al. Acute liver failure: clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000;6:163–169
  201. Wilkinson SP, Arroyo VA, Moodie H, et al. Abnormalities of sodium excretion and other disorders of renal function in fulminant hepatic failure. Gut. 1976;17:501–505
  202. Dawson DJ, Babbs C, Warnes TW, et al. Hypophosphataemia in acute liver failure. Br Med J (Clin Res Ed). 1987;295:1312–1313
  203. Knochel JP. The pathophysiology and clinical characteristics of severe hypophosphatemia. Arch Intern Med. 1977;137:203–220
  204. Schmidt LE, Dalhoff K. Serum phosphate is an early predictor of outcome in severe acetaminophen-induced hepatotoxicity. Hepatology. 2002;36:659–665
  205. Chung PY, Sitrin MD, Te HS. Serum phosphorus levels predict clinical outcome in fulminant hepatic failure. Liver Transpl. 2003;9:248–253
  206. Baquerizo A, Anselmo D, Shackleton C, et al. Phosphorus ans an early predictive factor in patients with acute liver failure. Transplantation. 2003;75:2007–2014
  207. Macquillan GC, Seyam MS, Nightingale P, et al. Blood lactate but not serum phosphate levels can predict patient outcome in fulminant hepatic failure. Liver Transpl. 2005;11:1073–1079
  208. Record CO, Iles RA, Cohen RD, et al. Acid-base and metabolic disturbances in fulminant hepatic failure. Gut. 1975;16:144–149
  209. Record CO, Chase RA, Williams R, et al. Disturbances of lactate metabolism in patients with liver damage due to paracetamol overdose. Metabolism. 1981;30:638–643
  210. Record CO, Chase RA, Alberti KG, et al. Disturbances in glucose metabolism in patients with liver damage due to paracetamol overdose. Clin Sci Mol Med. 1975;49:473–479
  211. Vilstrup H, Iversen J, Tygstrup N. Glucoregulation in acute liver failure. Eur J Clin Invest. 1986;16:193–197
  212. Stadler J, Barton D, Beil-Moeller H, et al. Hepatocyte nitric oxide biosynthesis inhibits glucose output and competes with urea synthesis for L-arginine. Am J Physiol. 1995;268:G183–G188
  213. Schneeweiss B, Pammer J, Ratheiser K, et al. Energy metabolism in acute hepatic failure. Gastroenterology. 1993;105:1515–1521
  214. Martin LF, Booth FV, Reines HD, et al. Stress ulcers and organ failure in intubated patients in surgical intensive care units. Ann Surg. 1992;215:332–337
  215. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients (Canadian Critical Care Trials Group). N Engl J Med. 1994;330:377–381
  216. Smilkstein MJ, Knapp GL, Kulig KW, et al. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdoser (Analysis of the national multicenter study (1976 to 1985)). N Engl J Med. 1988;319:1557–1562
  217. Lee WM. Drug-induced hepatotoxicity. N Engl J Med. 2003;349:474–485
  218. Tan C, Graudins A. Comparative pharmacokinetics of Panadol Extend and immediate-release paracetamol in a simulated overdose model. Emerg Med Australas. 2006;18:398–403
  219. Buckpitt AR, Rollins DE, Mitchell JR. Varying effects of sulfhydryl nucleophiles on acetaminophen oxidation and sulfhydryl adduct formation. Biochem Pharmacol. 1979;28:2941–2946
  220. Lin JH, Levy G. Sulfate depletion after acetaminophen administration and replenishment by infusion of sodium sulfate or N-acetylcysteine in rats. Biochem Pharmacol. 1981;30:2723–2725
  221. Miners JO, Drew R, Birkett DJ. Mechanism of action of paracetamol protective agents in mice in vivo. Biochem Pharmacol. 1984;33:2995–3000
  222. Corcoran GB, Todd EL, Racz WJ, et al. Effects of N-acetylcysteine on the disposition and metabolism of acetaminophen in mice. J Pharmacol Exp Ther. 1985;232:857–863
  223. Slattery JT, Wilson JM, Kalhorn TF, et al. Dose-dependent pharmacokinetics of acetaminophen: evidence of glutathione depletion in humans. Clin Pharmacol Ther. 1987;41:413–418
  224. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcystine: the treatment of choice for paracetamol poisoning. BMJ. 1979;2:1097–1100
  225. Prescott LF, Illingworth RN, Critchley JA, et al. Intravenous N-acetylcysteine: still the treatment of choice for paracetamol poisoning. BMJ. 1980;280:46–47
  226. Bernal W, Wendon J, Rela M, et al. Use and outcome of liver transplantation in acetaminophen-induced acute liver failure. Hepatology. 1998;27:1050–1055
  227. Holdiness MR. Clinical pharmacokinetics of N-acetylcysteine. Clin Pharmacokinet. 1991;20:123–134
  228. Harrison PM, Keays R, Bray GP, et al. Improved outcome of paracetamol-induced fulminant hepatic failure by late administration of acetylcysteine. Lancet. 1990;335:1572–1573
  229. Harrison PM, Wendon JA, Gimson AE, et al. Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure. N Engl J Med. 1991;324:1852–1857
  230. Keays R, Harrison PM, Wendon JA, et al. Intravenous acetylcysteine in paracetamol induced fulminant hepatic failure: a prospective controlled trial. BMJ. 1991;303:1026–1029
  231. Jones AL. Mechanism of action and value of N-acetylcysteine in the treatment of early and late acetaminophen poisoning: a critical review. J Toxicol Clin Toxicol. 1998;36:277–285
  232. Piperno E, Berssenbruegge DA. Reversal of experimental paracetamol toxicosis with N-acetylcysteine. Lancet. 1976;2:738–739
  233. Vale JA, Proudfoot AT. Paracetamol (acetaminophen) poisoning. Lancet. 1995;346:547–552
  234. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med. 1971;40:159–185
  235. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet. 1973;1:735–737
  236. Soloway RD, Summerskill WH, Baggenstoss AH, et al. J. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology. 1972;63:820–833
  237. Czaja AJ, Rakela J, Ludwig J. Features reflective of early prognosis in corticosteroid-treated severe autoimmune chronic active hepatitis. Gastroenterology. 1988;95:448–453
  238. Maggiore G, Porta G, Bernard O, et al. Autoimmune hepatitis with initial presentation as acute hepatic failure in young children. J Pediatr. 1990;116:280–282
  239. Bosch J, Coll M, Puig A, et al. Autoimmune hepatitis with fatal outcome. J Pediatr. 1991;118:823–824
  240. Nikias GA, Batts KP, Czaja AJ. The nature and prognostic implications of autoimmune hepatitis with an acute presentation. J Hepatol. 1994;21:866–871
  241. Viruet EJ, Torres EA. Steroid therapy in fulminant hepatic failure secondary to autoimmune hepatitis. P R Health Sci J. 1998;17:297–300
  242. Ichai P, Duclos-Vallee JC, Guettier C, et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl. 2007;13:996–1003
  243. Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl. 2007;13:953–955
  244. Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson's disease. J Hepatol. 1995;23:373–381
  245. Sternlieb I. Wilson's disease: indications for liver transplants. Hepatology. 1984;4:15S–17S
  246. Stampfl DA, Munoz SJ, Moritz MJ, et al. Heterotopic liver transplantation for fulminant Wilson's disease. Gastroenterology. 1990;99:1834–1836
  247. Williams R, Wendon J. Indications for orthotopic liver transplantation in fulminant liver failure. Hepatology. 1994;20:S5–S10S
  248. UNOS. Policies and Bylaws. 2007;
  249. Lake JR, Sussman NL. Determining prognosis in patients with fulminant hepatic failure: when you absolutely, positively have to know the answer. Hepatology. 1995;21:879–882
  250. Knaus WA, Wagner DP, Draper EA, et al. The APACHE III prognostic system (Risk prediction of hospital mortality for critically ill hospitalized adults). Chest. 1991;100:1619–1636
  251. Pereira LM, Langley PG, Hayllar KM, et al. Coagulation factor V and VIII/V ratio as predictors of outcome in paracetamol induced fulminant hepatic failure: relation to other prognostic indicators. Gut. 1992;33:98–102
  252. Bernuau J. Selection for emergency liver transplantation. J Hepatol. 1993;19:486–487
  253. Mitchell I, Bihari D, Chang R, et al. Earlier identification of patients at risk from acetaminophen-induced acute liver failure. Crit Care Med. 1998;26:279–284
  254. Schiodt FV, Rossaro L, Stravitz RT, et al. Gc-globulin and prognosis in acute liver failure. Liver Transpl. 2005;11:1223–1227
  255. Antoniades CG, Berry PA, Bruce M, et al. Actin-free Gc globulin: a rapidly assessed biomarker of organ dysfunction in acute liver failure and cirrhosis. Liver Transpl. 2007;13:1254–1261
  256. Bernuau J, Goudeau A, Poynard T, et al. Multivariate analysis of prognostic factors in fulminant hepatitis B. Hepatology. 1986;6:648–651
  257. Bernuau J, Samuel D, Durand F, et al. Criteria for emergency liver transplantation in patients with acute viral hepatitis and factor V below 50% of normal: a prospective study. 14 ed.. 1991;

PII: S0011-5029(08)00043-6

doi: 10.1016/j.disamonth.2008.03.008

Disease-A-Month
Volume 54, Issue 7 , Pages 457-485 , July 2008

Article Tools